Infrequent Mutations in the PTEN/MMAC1 Gene among Primary Breast Cancers

Recently PTEN/MMAC1, a candidate tumor suppressor gene, was isolated from chromosome 10q23‐24 and somatic mutations of this gene were detected in several malignancies including brain, prostate, and breast tumors. To investigate further the potential role of this gene in mammary carcinogenesis, we examined 69 primary breast cancers for mutations in PTEN/MMAC1 by means of polymerase chain reaction single‐strand conformation polymorphism and sequencing analysis. We detected only one somatic missense mutation, a change from T to C at codon 59 (TCA to CCA) resulting in substitution of Pro for Ser in the predicted protein. This site is located outside of phosphatase or phosphate‐acceptor motifs, but this codon encodes a residue that is conserved in homologous proteins, tensin and auxilin and is likely to be crucial for normal function of PTEN/MMAC1. Among the 69 tumors examined, three low‐frequency polymorphisms were found as well, one in the non‐coding region of exon 1 and one each in introns 2 and 7. Our results suggested that mutation of the PTEN/MMAC1 gene is not a major factor in the development of most primary breast cancers.

[1]  C. Eng,et al.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome , 1997, Nature Genetics.

[2]  M. Nelen,et al.  Germline mutations in the PTEN/MMAC1 gene in patients with Cowden disease. , 1997, Human molecular genetics.

[3]  Jing Li,et al.  Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.

[4]  W. K. Alfred Yung,et al.  Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.

[5]  M. Wigler,et al.  PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.

[6]  M. Becich,et al.  Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. , 1997, The American journal of pathology.

[7]  M. Ittmann.  Loss of heterozygosity on chromosomes 10 and 17 in clinically localized prostate carcinoma , 1996, The Prostate.

[8]  R. Schäfer,et al.  P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. , 1994, Anticancer research.

[9]  O. Cussenot,et al.  Genetic alterations in localized prostate cancer: Identification of a common region of deletion on chromosome arm 18q , 1994, Genes, chromosomes & cancer.

[10]  R. McLendon,et al.  Alterations of the TP53 gene in human gliomas. , 1994, Cancer research.

[11]  Y. Yuasa,et al.  Optimization of nonradioisotopic single strand conformation polymorphism analysis with a conventional minislab gel electrophoresis apparatus. , 1993, Analytical biochemistry.

[12]  A. Tanigami,et al.  Allelotype of breast cancer: cumulative allele losses promote tumor progression in primary breast cancer. , 1990, Cancer research.

[13]  D. Bigner,et al.  Specific chromosomal abnormalities in malignant human gliomas. , 1988, Cancer research.

[14]  Shinichiro,et al.  Carcinoma , 1906, The Hospital.

[15]  G. Sourvinos,et al.  Microsatellite instability and loss of heterozygosity in primary breast tumours. , 1997, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.